Cellular Therapy in Pediatric Hematologic Malignancies

Susan Kuldanek; Bryce Pasko; Melkon DomBourian; Kyle Annen

doi:10.1016/j.cll.2020.10.008

Cellular Therapy in Pediatric Hematologic Malignancies

Clin Lab Med. 2021 Mar;41(1):121-132. doi: 10.1016/j.cll.2020.10.008.

Authors

Susan Kuldanek¹, Bryce Pasko², Melkon DomBourian³, Kyle Annen⁴

Affiliations

¹ Hemophilia and Thrombosis Center, Center for Cancer and Blood Disorders, Children's Hospital Colorado, University of Colorado-Anschutz Medical Campus, 13123 East 16th Avenue, Aurora, CO 80045, USA.
² Department of Pathology and Laboratory Medicine, University of Colorado-Anschutz Medical Campus, Aurora, CO, USA; Department of Pathology, University of Colorado-Anschutz Medical Campus, Aurora, CO, USA.
³ Main Core Laboratory and Point of Care Testing, Department of Pathology and Laboratory Medicine, Children's Hospital Colorado, 13123 East 16th Avenue, B120, Aurora, CO 80045, USA; Department of Pathology, University of Colorado-Anschutz Medical Campus, Aurora, CO, USA.
⁴ Department of Pathology and Laboratory Medicine, University of Colorado-Anschutz Medical Campus, Aurora, CO, USA; Department of Pathology, University of Colorado-Anschutz Medical Campus, Aurora, CO, USA. Electronic address: kyle.annen@childrenscolorado.org.

PMID: 33494880
DOI: 10.1016/j.cll.2020.10.008

Abstract

Advances in cellular therapies for pediatric patients have created many opportunities for improved survival with reduced morbidity. This article reviews current cellular therapies in pediatric hematological malignancy, including the most updated practices in hematopoietic stem cell transplant and the use of chimeric antigen receptor (CAR) therapy in T cells. Hematopoietic stem cell transplant has evolved with improvements in chemotherapy regimens, immunosuppression, and donor-matching options. Novel therapies in development which will likely further improve the options for patients are reviewed including Natural Killer, Regulatory T-cells and αβ depletion.

Keywords: CAR T cell; Cord blood expansion; HPSC; NK cell therapy; Pediatric; Regulatory.

Publication types

Review

MeSH terms

Cell- and Tissue-Based Therapy
Hematologic Neoplasms* / therapy
Hematopoietic Stem Cell Transplantation*
Humans
Immunotherapy, Adoptive
Neoplasms*